Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical oxybutynin for neurogenic detrusor overactivity in adults
2009-011843-38Phase 3Completed
- Sponsor
- Grachtenhaus-Apotheke
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of oxybutynin in detrusor hyperreflexia (DH) and neurogenic bladder, sponsored by Grachtenhaus-Apotheke. Primary endpoint: Change in maximal cystometric bladder capacity. Started Sep 2009; status: completed.
02
Drugs
oxybutynin
03
Conditions
detrusor hyperreflexia (DH)neurogenic bladder
Beyond the preview
Go deeper on 2009-011843-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011843-38.